Filing Details

Accession Number:
0001209191-19-056486
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-13 20:01:49
Reporting Period:
2019-11-11
Accepted Time:
2019-11-13 20:01:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
897448 Amarin Corp Plc AMRN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1199637 F John Thero C/O Amarin Pharma, Inc.
440 Us Highway 22
Bridgewater NJ 08807
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2019-11-11 433,805 $17.05 2,658,480 No 4 S Direct
Ordinary Shares Disposition 2019-11-11 41,741 $17.88 2,616,739 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2017 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K.
  2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. Please see the section titled "Remarks" below for additional information.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $17.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.